Global Molecular Diagnostics Deal Trends, Players, Financials and Forecasts 2010-2015

Sep 23, 2015, 10:10 ET from Research and Markets

DUBLIN, Sept. 23, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/8hkj93/global_molecular) has announced the addition of the "Global Molecular Diagnostics 2010-2015: Deal trends, players, financials and forecasts" report to their offering.

The Global Molecular Diagnostics 2010-2015 report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest molecular diagnostics agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all molecular diagnostics partnering deals announced since 2010 including financial terms where available including over 300 links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sub-licensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law? The initial chapters of the report provide an orientation of molecular diagnostics dealmaking and its associated business and partnering activities. This chapter provides an overall introduction to the report and what you will learn from it, whilst chapter 2 provides an overview of the trends in molecular diagnostics deal making since 2010, categorizing by deal type, industry sector, stage of development and technology type.

A popular chapter with readers chapter 3 covers the average financial deal terms for deals signed in the molecular diagnostics field with a stage of development announced. Deals are listed and sectioned by average headlines, upfront payments, milestone payments and royalty rates. The median values of these deals are then presented by stage of development at signing. Numerous tables and figures are weaved within the report to support the findings and illustrate the trends and activities in molecular diagnostics partnering and dealmaking since 2010.

Chapter 4 covers the leading cancer diagnostics deals that have been announced over the past five years. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Full deal contract documents where available for each deal are indicated by a yes/no symbol. Within this chapter the most active molecular diagnostics deal makers are also listed as well as the deal making activities and the number of deals entered into by the big pharma companies.

Chapter 5 acts as a contracts reference directory chapter providing a full comprehensive and detailed list of the cancer diagnostics partnering deals signed and announced since January 2010. This chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy focus. In order for readers to view full details of each agreement the report is formatted so that each deal title links via Weblink to an online version of the actual deal at Current Agreements (www.currentagreements.com) deals and alliances database.

Chapter 6 brings the report to a conclusion by looking ahead to the future of molecular diagnostics partnering. Newly introduced to provide readers with potential prospects and partnering insights this chapter selects emerging companies to watch in 2015 and details their recent deal making and financial activities. These companies could be potential targets for those who want to invest or partner in the coming months.

In conclusion, this report gives prospective dealmakers a thorough overview of all the deals announced in the molecular diagnostics field preparing them with everything they need to know about partnering in the research, development and commercialization of cancer diagnostics technologies and products.

A full appendix is provided at the very end of the report which lists all the cancer diagnostics deals announced since 2010 categorized by company A-Z, deal type, stage of development, technology and therapy. Where available contract documents are supplied, these documents include additional deal information in comparison to only the brief summary that is provided through a press release. Readers can analyze the contracts fully by reviewing the detailed terms between the parties under which monies and licensing rights are exchanged. The appendix is useful for looking at all the deals signed by one specific company.

Executive Summary:

Global Molecular Diagnotsics Partnering 2010-2015 provides the reader with the following key benefits:

- In-depth understanding of molecular diagnostics deal trends since 2010.

- Access molecular diagnostics deal headline, upfront, milestone and royalty data.

- Analysis of the structure of molecular diagnostics agreements with numerous real life case studies.

- Comprehensive access to over 300 links to actual infectious vaccines deals entered into by the world's biopharma companies, together with real world clause examples.

- Identify leading molecular diagnostics deals by value since 2010.

- Identify the most active molecular diagnostics dealmakers since 2010.

- Insight into the terms included in molecular diagnostics agreement, together with real world clause examples.

- Understand the key deal terms companies have agreed in previous deals.

- Undertake due diligence to assess suitability of your proposed deal terms for partner companies. Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in molecular diagnostics dealmaking

2.1. Introduction

2.2. Molecular diagnostics partnering over the years

2.3. Molecular diagnostics partnering by industry type

2.4. Molecular diagnostics partnering by deal type

2.5. Molecular diagnostics partnering by disease type

2.6. Molecular diagnostics partnering by stage of development

Chapter 3 - Average financial deal terms for molecular diagnostics partnering 3.1. Introduction 3.2. Disclosed financials terms for molecular diagnostics partnering 3.2.1 Molecular diagnostics partnering headline values 3.2.2 Molecular diagnostics upfront payments 3.2.3 Molecular diagnostics milestone payments 3.2.4 Molecular diagnostics royalty rates

Chapter 4 - Leading molecular diagnostics deals

4.1. Introduction

4.2. Top molecular diagnostics deals by value

4.3. Most active in molecular diagnostics partnering

4.4. Big pharma molecular diagnostics dealmaking activity

4.5. Big pharma molecular diagnostics partnering company profiles

Chapter 5 - Molecular diagnostics partnering contracts directory 5.1. Introduction 5.2. Company A-Z 5.3. By deal type 5.4. By stage of development 5.5. By therapy area

Chapter 6 - Molecular diagnostics dealmaking directory

6.1. Introduction

6.2. Deals by molecular diagnostics type, includes theranostics

Chapter 7 - Future trends and companies in molecular diagnostics deal making 7.1. Introduction 7.2. Emerging companies to watch in 2015 7.3. Emerging companies dealmaking in 2010-2015 7.4. Emerging company financings in 2010-2015 7.5 Conclusion

Appendices

Introduction

Appendix 1 - Directory of molecular diagnostics deals by company A-Z 2010 to 2015

Appendix 2 - Directory of molecular diagnostics deals by stage of development 2010 to 2015

Appendix 3 - Directory of molecular diagnostics deals by deal type 2010 to 2015

Appendix 4 - Directory of molecular diagnostics deals by therapy area 2010 to 2015

Appendix 5 - Molecular diagnostics partnering resource center

Online molecular diagnostics partnering

The anatomy of molecular diagnostics partnering

The anatomy of a molecular diagnostics deal

Molecular Diagnostics partnering events

Further reading on molecular diagnostics dealmaking

Table of figures: Figure 1: Molecular diagnostics partnering since 2010 Figure 2: Molecular diagnostics partnering by industry sector since 2010 Figure 3: Molecular diagnostics partnering by deal type since 2010 Figure 4: Molecular diagnostics partnering by disease type since 2010 Figure 5: Molecular diagnostics partnering by stage of development since 2010 Figure 6: Molecular diagnostics deals with a headline value by year- 2015 Figure 7: Molecular diagnostics deals with a headline value by year- 2014 Figure 8: Molecular diagnostics deals with a headline value by year- 2013 Figure 9: Molecular diagnostics deals with a headline value by year- 2012 Figure 10: Molecular diagnostics deals with a headline value by year- 2011 Figure 11: Molecular diagnostics deals with a headline value by year- 2010 Figure 12: Molecular diagnostics deals with an upfront value by year- 2015 Figure 13: Molecular diagnostics deals with an upfront value by year- 2014 Figure 14: Molecular diagnostics deals with an upfront value by year- 2013 Figure 15: Molecular diagnostics deals with an upfront value by year- 2012 Figure 16: Molecular diagnostics deals with an upfront value by year- 2011 Figure 17: Molecular diagnostics deals with an upfront value by year- 2010 Figure 18: Molecular diagnostics deals with a milestone value by year- 2015 Figure 19: Molecular diagnostics deals with a milestone value by year- 2014 Figure 20: Molecular diagnostics deals with a milestone value by year- 2013 Figure 21: Molecular diagnostics deals with a milestone value by year- 2012 Figure 22: Molecular diagnostics deals with a milestone value by year- 2011 Figure 23: Molecular diagnostics deals with a milestone value by year- 2010 Figure 24: Molecular diagnostics deals with a royalty rate value by year- 2015 Figure 25: Molecular diagnostics deals with a royalty rate value by year- 2014 Figure 26: Molecular diagnostics deals with a royalty rate value by year- 2013 Figure 27: Molecular diagnostics deals with a royalty rate value by year- 2012 Figure 28: Molecular diagnostics deals with a royalty rate value by year- 2011 Figure 29: Molecular diagnostics deals with a royalty rate value by year- 2010 Figure 30: Top molecular diagnostics deals by value since 2010 Figure 31: Active molecular diagnostics dealmaking activity- 2010 to 2015 Figure 32: Big pharma - top 50 - Molecular diagnostics deals 2010 to 2015 Figure 33: Big pharma molecular diagnostics deal frequency - 2010 to 2015 Figure 34: Online partnering resources Figure 35: Components of the typical molecular diagnostics deal structure Figure 36: Forthcoming partnering events

For more information visit http://www.researchandmarkets.com/research/8hkj93/global_molecular

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

 

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com